Telmisartan and Nosebleed - a phase IV clinical study of FDA data

Summary:

Nosebleed is reported as a side effect among people who take Telmisartan (telmisartan), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Amlodipine, and have Breast cancer female.

The phase IV clinical study analyzes which people have Nosebleed when taking Telmisartan. It is created by eHealthMe based on reports of 8,644 people who have side effects when taking Telmisartan from the FDA, and is updated regularly.

What is Telmisartan?

Telmisartan has active ingredients of telmisartan. It is often used in high blood pressure. eHealthMe is studying from 9,163 Telmisartan users. Check the latest studies of Telmisartan.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,074 drugs and 3,093 conditions by eHealthMe. Check the latest studies of Nosebleed.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

8,644 people reported to have side effects when taking Telmisartan.
Among them, 40 people (0.46%) have Nosebleed.

Among these 40 people:

How long have people been on Telmisartan when they have Nosebleed? *

What is the gender of people who have Nosebleed when taking Telmisartan? *

female: 50 %
male: 50 %

What is the age of people who have Nosebleed when taking Telmisartan? *

What are other drugs people take besides Telmisartan? *

What are other side effects people have besides Nosebleed? *

Thrombocytopenia (decrease of platelets in blood): 9 people, 22.50%
Anaemia (lack of blood): 7 people, 17.50%
Weakness: 6 people, 15.00%
Urinary Tract Infection: 6 people, 15.00%
Neuropathy Peripheral (surface nerve damage): 6 people, 15.00%
Diarrhea: 6 people, 15.00%
Fatigue (feeling of tiredness): 6 people, 15.00%
Constipation: 5 people, 12.50%
Sinusitis (inflammation of sinus): 5 people, 12.50%
Haematuria (presence of blood in urine): 5 people, 12.50%

What are the existing conditions these people have? *

Breast Cancer Female: 5 people, 12.50%
Peripheral Ischaemia (impaired circulation to an extremity): 3 people, 7.50%
Pain: 3 people, 7.50%
Primary Myelofibrosis (primary disorder of the bone marrow): 2 people, 5.00%
Colon Cancer: 2 people, 5.00%
Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 5.00%
Urination - Painful: 1 person, 2.50%
Glioblastoma (most common and most aggressive malignant primary brain tumour in humans): 1 person, 2.50%
Back Pain: 1 person, 2.50%
Breast Cancer Metastatic: 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Telmisartan and have Nosebleed?

- Check whether Nosebleed is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Telmisartan:

Telmisartan (9,163 reports)

Nosebleed treatments and more:

Nosebleed (92,075 reports)

Browse all side effects of Telmisartan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nosebleed:

Nosebleed (2,074 drugs)

Browse all the conditions that are associated with Nosebleed:

Nosebleed (3,093 conditions)

Related publications that referenced our studies

Kato Y, Mukai Y, Rane A, Inotsume N, Toda T, "The inhibitory effect of telmisartan on the metabolism of arachidonic acid by CYP2C9 and CYP2C8: an in vitro study", Biological and Pharmaceutical Bulletin, 2017 Sep .
Kim HK, Youm JB, Lee SR, Lim SE, Lee SY, Ko TH, Nilius B, Noh JH, Ko KS, Rhee BD, Kim N, "The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action", Pflügers Archiv-European Journal of Physiology, 2012 Dec .
Kato Y, Mukai Y, Rane A, Inotsume N, Toda T, "The inhibitory effect of telmisartan on the metabolism of arachidonic acid by CYP2C9 and CYP2C8: an in vitro study", Biological and Pharmaceutical Bulletin, 2017 Sep .
Kim HK, Youm JB, Lee SR, Lim SE, Lee SY, Ko TH, Nilius B, Noh JH, Ko KS, Rhee BD, Kim N, "The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action", Pflügers Archiv-European Journal of Physiology, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on telmisartan (the active ingredients of Telmisartan) and Telmisartan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.